2014-16年抗生素耐药性调查(SOAR)在乌克兰和斯洛伐克共和国的结果
该调查测定了2014-16年乌克兰和斯洛伐克共和国分离的肺炎链球菌和流感嗜血杆菌的抗生素敏感性。乌克兰肺炎链球菌对阿莫西林等敏感性≥97%,斯洛伐克共和国对青霉素等仅61%-64%、大环内酯类仅44%。两国流感嗜血杆菌对多数药物敏感性>90%,但不同折点间差异大。
要点
- 乌克兰肺炎链球菌对阿莫西林、阿莫西林/克拉维酸、青霉素(静脉非脑膜炎)和氟喹诺酮类敏感性≥97%。
- 斯洛伐克共和国肺炎链球菌对青霉素、阿莫西林、阿莫西林/克拉维酸、头孢呋辛和甲氧苄啶/磺胺甲噁唑敏感性61%-64%,大环内酯类仅44%。
- 两国流感嗜血杆菌对阿莫西林/克拉维酸、头孢曲松、头孢呋辛、阿奇霉素和氟喹诺酮类按CLSI标准敏感性>90%。
核心结论
- 两个邻国间的耐药性差异说明需监测并公布国家和局部耐药模式,这对有效经验性治疗至关重要,也可用于帮助制定和支持抗菌药物管理措施以限制抗生素耐药。
研究设计与样本
- 研究测定了2014-16年从乌克兰和斯洛伐克共和国收集的肺炎链球菌和流感嗜血杆菌分离株的MIC。
- MIC采用CLSI肉汤微量稀释法测定,敏感性采用CLSI、EUCAST和药代动力学/药效学(PK/PD)折点评估。
主要发现
- 乌克兰肺炎链球菌分离株(n=100)对阿莫西林、阿莫西林/克拉维酸、青霉素(静脉非脑膜炎)和氟喹诺酮类敏感性≥97%,对口服青霉素、大环内酯类和头孢克洛敏感性83%-86%,对甲氧苄啶/磺胺甲噁唑敏感性75%。
- 斯洛伐克共和国肺炎链球菌分离株(n=95)对氟喹诺酮类全部敏感,但对青霉素、阿莫西林、阿莫西林/克拉维酸、头孢呋辛和甲氧苄啶/磺胺甲噁唑敏感性61%-64%,对大环内酯类仅44%敏感。
- 两国流感嗜血杆菌对阿莫西林/克拉维酸、头孢曲松、头孢呋辛、阿奇霉素和氟喹诺酮类的敏感性按CLSI标准>90%,不同折点间差异较大,尤其对阿奇霉素、头孢克洛和头孢呋辛。
- β-内酰胺酶率在斯洛伐克共和国为5.1%(5/98),在乌克兰为7.3%(7/96);斯洛伐克共和国还有相对较高的β-内酰胺酶阴性氨苄西林耐药(BLNAR)分离株率(7.1%;7/98)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine antibiotic susceptibility in isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from Ukraine and the Slovak Republic. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae isolates collected in Ukraine (n = 100) showed susceptibility rates ≥97% for amoxicillin, amoxicillin/clavulanic acid, penicillin [intravenous (iv) non-meningitis] and fluoroquinolones, between 83% and 86% for oral penicillin, macrolides and cefaclor, and 75% for trimethoprim/sulfamethoxazole. Susceptibility was substantially lower in the Slovak Republic (n = 95). All isolates were susceptible to the fluoroquinolones, but susceptibility to penicillin, amoxicillin, amoxicillin/clavulanic acid, cefuroxime and trimethoprim/sulfamethoxazole varied between 61% and 64%, with only 44% of isolates susceptible to the macrolides. Susceptibility of H. influenzae was more homogeneous, with susceptibility to amoxicillin/clavulanic acid, ceftriaxone, cefuroxime, azithromycin and the fluoroquinolones seen in >90% of isolates by CLSI criteria in both countries. Much greater variability was seen across breakpoints, especially for azithromycin, cefaclor and cefuroxime. The β-lactamase rate was 5.1% (5/98) in the Slovak Republic and 7.3% (7/96) in Ukraine, but the Slovak Republic also had a relatively high rate of β-lactamase-negative-ampicillin-resistant (BLNAR) isolates (7.1%; 7/98). CONCLUSIONS: The variability found across these two neighbouring countries illustrates the need to monitor and publish national and local resistance patterns. This information is not only critical for effective empirical therapy but can also be used to help shape and support antimicrobial stewardship efforts in order to limit antibiotic resistance.
引用
- Torumkuney D, Pertseva T, Bratus E, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Ukraine and the Slovak Republic. J Antimicrob Chemother. 2018. PMID: 29659885. doi:10.1093/jac/dky069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。